<unk>  (17β-deacetyl-NETA), the active form of<unk> .<unk>  and ethinylestradiol levels over 24 hours after a single oral dose of 10 mg<unk>  in postmenopausal women.<unk>  is a prodrug of<unk>  in the body. Upon oral ingestion, it is rapidly converted into<unk>  by esterases during intestinal and first-pass hepatic metabolism. Hence, as a prodrug of<unk> ,<unk>  has essentially the same effects, acting as a potent progestogen with additional weak androgenic and estrogenic activity (the latter via its metabolite ethinylestradiol). In terms of dosage equivalence,<unk>  and<unk>  are typically used at respective dosages of 0.35 mg/day and 0.6 mg/day as progestogen-only contraceptives, and at respective dosages of 0.5–1 mg/day and 1–1.5 mg/day in combination with ethinylestradiol in combined oral contraceptives. Conversely, the two drugs have been used at about the same dosages in menopausal hormone therapy for the treatment of menopausal symptoms.<unk>  is of about 12% higher molecular weight than<unk>  due to the presence of its C17β<unk>  ester. Micronization of<unk>  has been found to increase its potency by several-fold in animals and women. The endometrial transformation dosage of micronized<unk>  per cycle is 12 to 14 mg, whereas that for non-micronized<unk>  is 30 to 60 mg.<unk>  metabolizes into ethinylestradiol at a rate of 0.20 to 0.33% across a dose range of 10 to 40 mg. Peak levels of ethinylestradiol with a 10, 20, or 40 mg dose of<unk>  were 58, 178, and 231 pg/mL, respectively. For comparison, a 30 to 40 μg dose of oral ethinylestradiol typically results in a peak ethinylestradiol level of 100 to 135 pg/mL. As such, in terms of ethinylestradiol exposure, 10 to 20 mg<unk>  may be equivalent to 20 to 30 μg ethinylestradiol and 40 mg<unk>  may be similar to 50 μg ethinylestradiol. Due to its estrogenic activity via ethinylestradiol, high doses of<unk>  have been proposed for add-back in the treatment of endometriosis without estrogen supplementation. Generation of ethinylestradiol with high doses of<unk>  may increase the risk of venous thromboembolism.
Norethisterone acetate
Norethisterone enanthate
Nandrolone propionate
Androstanolone benzoate
Nandrolone hydrogen succinate
Nandrolone cypionate
Nandrolone decanoate
Nandrolone phenylpropionate